NCT01547741 is a Phase 3 clinical trial of Doxorubicin in Breast Cancer, sponsored by NSABP Foundation Inc.

Who is sponsoring NCT01547741?

NCT01547741 is sponsored by NSABP Foundation Inc.

What drugs are being tested in NCT01547741?

Interventions in NCT01547741: Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel.

What condition does NCT01547741 study?

NCT01547741 studies Breast Cancer.

Is NCT01547741 still recruiting?

NCT01547741 is currently status unknown. Last updated 13 April 2022.

Last reviewed 2022-04-13 · How we verify

NCT01547741

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Status unknown Phase 3 Last updated 13 April 2022

What this trial tests

Phase 3 trial testing Doxorubicin in Breast Cancer in 1,871 participants. Status unknown.

Timeline

1 April 2012

Primary endpoint
1 May 2022

1 November 2023

Quick facts

Lead sponsor	NSABP Foundation Inc
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,871
Start date	1 April 2012
Primary completion	1 May 2022
Estimated completion	1 November 2023
Sites	915 locations across United States, Puerto Rico

Drugs / interventions tested

Doxorubicin (doxorubicin) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Docetaxel (Docetaxel) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

NSABP Foundation Inc

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Invasive disease-free survival (IDFS)
Time frame: Assessed before each cycle of chemotherapy, 3-4 weeks after completion of chemotherapy, every 6 months through 5 years and yearly years 6-10.
The time to local recurrence following mastectomy, invasive local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, invasive contralateral breast cancer, second primary cancer (other than squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, colorectal carcinoma in situ, or lobular carcinoma in situ of the

Sponsor's own description

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating women with non-metastatic breast cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Blum JL, Flynn PJ, Yothers G, Asmar L, et al · · 2017 · cited 201× · PMID 28398846 · DOI 10.1200/jco.2016.71.4147
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.
Eisen A, Fletcher GG, Gandhi S, Mates M, et al · · 2015 · cited 39× · PMID 25848340 · DOI 10.3747/co.22.2320
Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies.
MacDonald I, Nixon NA, Khan OF. · · 2022 · cited 29× · PMID 35877238 · DOI 10.3390/curroncol29070378
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Geyer CE, Blum JL, Yothers G, Asmar L, et al · · 2024 · cited 18× · PMID 38335467 · DOI 10.1200/jco.23.01428

Verify or expand the search:

Other trials of Doxorubicin

Trials testing the same drug.

NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other NSABP Foundation Inc trials

Trials by the same sponsor.

NCT07058012 — A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel · Phase 2 · not yet recruiting
NCT03628066 — Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Br · Phase 2 · completed
NCT03457896 — Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Col · Phase 2 · unknown
NCT03412643 — Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal · Phase 2 · unknown
NCT03102047 — Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01547741 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NSABP Foundation Inc
Last refreshed: 13 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01547741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing